Eli Lilly (NYSE:LLY) reported Phase 3 data showing its triple-agonist retatrutide outperformed Novo Nordisk's Ozempic in type 2 diabetes. The long term head to head trial indicated stronger glycemic control and weight loss effects for retatrutide than Ozempic in the study population. Lilly resolved a legal dispute with Novo Nordisk over product marketing and outlined a leadership reshuffle that consolidates global business units. Retatrutide's Phase 3 edge over Ozempic and Lilly's leadership overhaul are part of a broader shift our research has tracked. Our analysis turns up 1 warning sign for Eli Lilly as well.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.